Download PDFPDF

Perceptions of French general practitioners and patients regarding dextropropoxyphene withdrawal: a qualitative study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Toxicity of dextropropoxyphene

    This is an interesting article which provides useful insights for regulators. Unfortunately the authors state: 'DXP toxicity is mainly
    due to its long half-life (15–37 hours), and
    it can be increased by concomitant use of
    alcohol or sedative drugs', quoting 2 rather old references.
    We showed that deaths occurred before hospital admission, early in the course of poisoning, and postulated that this was likely due to the arrythmogenic effect of DXP, its main metabolite combined with the respiratory depressant effect the opioid action. This was one of the main reasons this drug was withdrawn in the UK, saving many hundreds of lives since withdrawal here. (Sandilands EA, Bateman DN. Co-proxamol withdrawal has reduced suicide from drugs in Scotland. British Journal of Clinical Pharmacology 2008; 66: 290-293.)

    Conflict of Interest:
    None declared.